Discover
ALGS
Aligos Therapeutics, Inc.
5.45
2 x 4.09
2 x 7.00
bid
ask
-
0.32
5.55%
2 @ 04:00 PM
5.45 +0.00 (0.00%)
| Ytd | -41.52% | |
| 1y | -26.25% |
5.44
day range
5.81
4.80
52 week range
13.69
| Open | 5.72 | Prev Close | 5.77 | Low | 5.44 | High | 5.81 | Mkt Cap | 33.73M |
| Vol | 67.28K | Avg Vol | 216.42K | EPS | -9.78 | P/E | N/A | Forward P/E | -3.30 |
| Beta | 2.12 | Short Ratio | 0.50 | Inst. Own | 48.86% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-06 | 50-d Avg | 5.75 | 200-d Avg | 7.86 | 1yr Est | 103.33 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-11-06 | 2024-09 | -2.15 | -3.07 | -0.92 | -42.79% |
| 2024-08-06 | 2024-06 | -4 | 0.75 | 4.75 | 118.75% |
| 2024-08-06 | 2024-06 | -4 | N/A | N/A | N/A |
| 2024-05-07 | 2024-03 | -4.75 | -5.5 | -0.75 | -15.79% |
| 2024-05-07 | 2024-03 | -4.75 | N/A | N/A | N/A |
| 2024-03-12 | 2023-12 | -6.75 | -5.5 | 1.25 | 18.52% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-11-07 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-10-23 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-09-20 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-08-19 | HC Wainwright & Co. | Upgrade | Buy | |
| 2023-01-17 | Piper Sandler | Upgrade | Overweight | |
| 2023-01-06 | Piper Sandler | Upgrade | Neutral | Overweight |
Profile
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB. In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. It also has a clinical collaboration with Xiamen Amoytop Biotech Co., Ltd. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2020-10-19 | BEIGELMAN LEONID | President | 0.00 | Conversion of Exercise of derivative security |
| 2023-10-24 | BLATT LAWRENCE M | Chief Executive Officer | 2.12M | Stock Award(Grant) |
| 2020-10-19 | NOVO HOLDINGS A/S | Beneficial Owner of more than 10% of a Class of Security | 2.61M | Purchase |
| 2023-10-24 | NUECHTERLEIN CAROLE L | Director and Beneficial Owner of more than 10% of a Class of Security | 0.00 | Purchase |
| 2023-10-24 | SCOPA JAMES PAUL | Director | 183.08K | Stock Award(Grant) |
| 2020-10-19 | SYMONS JULIAN A | Officer | 394.06K | Conversion of Exercise of derivative security |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Armistice Capital, LLC | 315.10K | 12.40M | 8.78% |
| 2024-09-29 | EcoR1 Capital, LLC | 255.57K | 10.05M | 7.12% |
| 2024-09-29 | Deep Track Capital, Lp | 244.11K | 9.60M | 6.80% |
| 2024-09-29 | Adage Capital Partners GP L.L.C. | 218.81K | 8.61M | 6.10% |
| 2024-09-29 | Vivo Capital, LLC | 141.88K | 5.58M | 3.95% |
| 2024-09-29 | Woodline Partners LP | 91.97K | 3.62M | 2.56% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Vanguard Total Stock Market Index Fund | 52.80K | 2.08M | 1.47% |
| 2024-10-30 | Fidelity Extended Market Index Fund | 12.39K | 487.42K | 0.35% |
| 2024-09-29 | Vanguard Extended Market Index Fund | 11.02K | 433.49K | 0.31% |
| 2024-10-30 | Fidelity Total Market Index Fund | 4.36K | 171.56K | 0.12% |
| 2024-10-30 | Fidelity Series Total Market Index Fund | 3.15K | 123.92K | 0.09% |
| 2024-07-30 | Schwab Capital Trust-Total Stock Market Index Fund | 1.25K | 49.37K | 0.03% |
Split
| Split | Date |
|---|---|
| 1 : 25 | 2024-08-19 |